CAJ | 학술논문

新一代口服氟尿嘧啶类衍生物卡培他滨和替吉奥(S-1)已广泛应用于老年患者的治疗,有一定疗效且不良反应较小.氟尿嘧啶类和铂类的联合方案可提高疗效,但同时也增加了不良反应的发生.三药联合方案的临床报道较少,且不良反应明显,疗效尚不确切.
신일대구복불뇨밀정류연생물잡배타빈화체길오(S-1)이엄범응용우노년환자적치료,유일정료효차불량반응교소.불뇨밀정류화박류적연합방안가제고료효,단동시야증가료불량반응적발생.삼약연합방안적림상보도교소,차불량반응명현,료효상불학절.
New oral fluoropyrimidines,such as capecitabine and S-1,have been widely used for elderly patients with a certain efficiency and slight toxicity.Fluorouracil combined with platinum program probably enhances the effectiveness,but also increases the incidence of adverse reactions.There are a few clinical reports about triple-drug combination for elderly patients,but the toxicity is obvious and the efficacy is not certain.